Incyte Corporation (INCY) :The total money flow, which is calculated as the dollar value of composite uptick minus downtick trades was negative ($17.37 million) and the uptick to downtick ratio was 0.55. The transaction value on upticks was $21.39 million and on downticks, the transaction value was $38.76 million. The transaction value of block trades during downticks was $17.53 million. The money flow was negative ($17.53 million), indicating the traders were booking profit on the price strength. Incyte Corporation (INCY) rose $1.21 at $82.02, during intraday Friday , a rise of 1.5% over the previous days close.
The company Insiders own 13.7% of Incyte Corporation shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -13.06% . Institutional Investors own 92.4% of Incyte Corporation shares. During last six month period, the net percent change held by insiders has seen a change of -13.06%.
In a related news,The officer (EVP, Chief Scientific Officer) of Incyte Corp, Huber Reid M sold 10,000 shares at $87.96 on August 2, 2016. The Insider selling transaction had a total value worth of $879,600. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Incyte Corporation (NASDAQ:INCY): The stock opened at $81.14 and touched an intraday high of $82.65 on Friday. During the day, the stock corrected to an intraday low of $80.5, however, the bulls stepped in and pushed the price higher to close in the green at $82.02 with a gain of 1.50% for the day. The total traded volume for the day was 1,131,127. The stock had closed at $80.81 in the previous trading session.
Incyte Corporation (INCY) has been under a strong bear grip, hence the stock is down -9.59% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 0.7% in the past 1 week. The stock has risen by 1.21% in the past week indicating that the buyers are active at lower levels, but the stock is down -9.71% in the past 4 weeks.
Incyte Corporation is a biopharmaceutical company focused on the discovery development and commercialization of small molecule drugs to treat serious unmet medical needs. The Companys compound JAKAFI (ruxolitinib) also known as INCB18424 and INC424 is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or highrisk myelofibrosis (MF) including primary MF postpolycythemia vera MF and postessential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor LY3009104 (INCB28050) , which is subject to a collaboration agreement with Eli Lilly and Company in , which Lilly received development and commercialization rights f